Cardiovascular and renal prognosis depends also on glycemic state

Czech version

Authors: Ján Murín
Authors‘ workplace: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in: Forum Diab 2022; 11(1): 56-59
Category: News

Overview

Treatment guidelines for pre-diabetes focus primarily on glycemic control and lifestyle management. Cardiovascular (CV) and renal outcomes of these patients is also dependent on their glycemic state. The UK Biobank is a prospective, observational, population-based cohort of adult residents in UK, who were 40–69 years old at the time of recruitment between 2006–2010. Among 336 709 individuals (mean age 56.3 ys, 55.4% female) an association of glycemic state (type 2 diabetes, T2D, in 12 717 patients, 3.8%; pre-diabetes in 46 911 patients, 13.9% and normoglycemic persons in 277 081, 82.3%) with outcomes (CV disease, chronic kidney disease, CKD and heart failure, HF) was tested (Cox model) over median of follow-up of 11.1 years. Pre-diabetes and T2D independently associated with CV disease (pre-diabetes with relative risk, RR, 1.11, S and T2D with RR 1.44, S), with CKD (pre-diabetes with RR 1.08, S and T2D with RR 1.57, S) and with HF (pre-diabetes with RR 1.07, S and T2D with RR 1.25, S). Pre-diabetes and T2D are associated with CV disease, with CKD and with HF. These finding highlight the need to design risk-reduction strategies across the glycemic spectrum.

Keywords:

heart failure – cardiovascular disease – type 2 diabetes – chronic kidney disease – pre-diabetes – prognosis of pre-diabetes and type 2 diabetes

Sources

1. Shah DA, Langenberg C, Rapsomaniki E et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: cohort study in 1.9 milion people. Lancet Diabetes Endocrinol 2015; 3(2):105–113. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(14)70219–0>.
2. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes. 1988–2014. JAMA 2016; 316(6): 602–610 Dostupné z DOI: <http://doi: 10.1001/jama.2016.10924>.
3. McAlllister D, Read SH, Kerssens J et al. Incidene of hospitalization for heart failure and case fatality among 3.25 million people with and without diabetes mellitus. Circulation 2018; 138(24): 2774–2786. Dostupné z DOI: <http://doi: 10.1161/CIRCULATIONAHA.118.034986>.
4. Rawashani A, Franzén S, Sattar N et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379(7): 633–644. Dostupné z DOI: <http://doi: 10.1056/
NEJMoa1800256>.
5. Berg DD, Wiviott SD, Scirica BM et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation 2019; 140(19): 1569–1577. Dostupné z DOI: <http://doi: 10.1161/CIRCULATIONAHA.119.042685>.
6. Kalyani RR. Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. N Engl J Med 2021; 384(13): 1248–1260. Dostupné z DOI: <http://doi: 10.1056/NEJMcp2000280>.
7. Andes LJ, Cheng YJ, Rolka DB, et al. Prevalence of prediabetes among adolescents and young adults in the United States 2005–2016. JAMA Pediatr 2020; 174(2): e194498. Dostupné z DOI: <http://doi:10.1001/jamapediatrics.2019.4498>.
8. Welsh C, Welsh P, Celis-Morales CA et al. Glycated hemoglobin, prediabetes, and the links to cardiovascular disease: data from UK Biobank. Diabetes Care 2020; 43(2): 440–445. Dostupné z DOI: <http://doi: 10.2337/dc19–1683>.
9. Cai X, Zhang Y, Li M et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ 2020; 370: m2297. Dostupné z DOI: <http://doi: 10.1136/bmj.m2297>.
10. Selvin E, Lazo M, Chen Y et al. Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage. Circulation 2014; 130(16): 1374–1382. Dostupné z DOI: <http://doi: 10.1161/CIRCULATIONAHA.114.010815>.
11. Skali H, Shah A, Gupta DK et al. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. Circ Heart Fail 2015; 8(3): 448–454. Dostupné z DOI: <http://doi:10.1161/CIRCHEARTFAILURE.114.001990>.
12. Bycroft C, Freeman C, Petkova D et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018; 562(7726): 203–209. Dostupné z DOI: <http://doi: 10.1038/s41586–018–0579-z>.
13. American Diabetes Association, 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes – 2021. Diabetes Care 2021; 44(Suppl 1): S34-S39. Dostupné z DOI: <http://doi: 10.2337/dc21-S003>.
14. Honigberg MC, Zekavat SM, Pirruccello JP et al. Cardiovascular and kidney outcomes across the glycemic spectrum. J Am Coll Cardiol. 2021; 78(5): 453–464. Dostupné z DOI: <http://doi: 10.1016/j.jacc.2021.05.004>.
15. Cole P, MacMahon B. Attributable risk per cent in case-control studies. Br J Prev Soc Med 1971; 25(4): 242–244. Dostupné z DOI: <http://doi: 10.1136/jech.25.4.242>.
16. de Jong M, Woodward M, Peters SAE. Diabetes, glycated hemoglobin, and the risk of myocardial infarction in women and men: a prospective cohort study of the UK Biobank. Diabetes Care 2020; 43(9): 2050–2059. Dostupné z DOI: <http://doi: 10.2337/dc19–2363>.
17. Kim HK, Lee JB, Kim SH et al. Association of prediabetes, defined by fasting glucose, HbA1c only, or combined criteria, with the risk of cardiovascular disease in Koreans. J Diabetes 2016; 8(5): 657–666. Dostupné z DOI: <http://doi: 10.1111/1753–0407.12343>.
18. Rooney MR, Rawlings AM, Pankow JS et al. Risk of progression to diabetes among older adults with prediabetes. JAMA Intern Med 2021; 181(4): 511–519. Dostupné z DOI: <http://doi: 10.1001/jamainternmed.2020.8774>.
19. American diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43(Suppl 1): S111-S134. Dostupné z DOI: <http://doi:10.2337/dc20-ad08>.
20. Wilding JPH, Batterham RL, Colanna S et al. STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384(11): 989–998. Dostupné z DOI: <http://doi: 10.1056/NEJMoa2032183>.
21. Anker SD, Butler J, Filippatos G et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial. Circulation 2021; 143(4): 337–349. Dostupné z DOI: <http://doi: 10.1161/CIRCULATIONAHA.120.051824>.
22. Wheeler DC, Stefánssson BV, Jongs N et al. DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021; 9(1): 22–31. Dostupné z DOI: <http://doi: 10.1016/S2213–8587(20)30369–7>.